Michael Knappik
@michael-knappik.bsky.social
ID specialist HIV/Tb 🩻🧫
Reposted by Michael Knappik
“We call on countries and the WHO to demand pharmaceutical corporations make these key diabetes treatments available in-country by immediately registering them and – critically – making them affordable.”
msfaccess.org/msf-responds...
msfaccess.org/msf-responds...
MSF responds to inclusion of rapid-acting insulin analogues and GLP-1s to WHO Essential Medicines List
MSF welcomes inclusion of key diabetes medicines to WHO EML, and calls for countries and WHO to demand corporations make them available and affordable.
msfaccess.org
September 5, 2025 at 2:41 PM
“We call on countries and the WHO to demand pharmaceutical corporations make these key diabetes treatments available in-country by immediately registering them and – critically – making them affordable.”
msfaccess.org/msf-responds...
msfaccess.org/msf-responds...
Reposted by Michael Knappik
Insulin pens must be affordable and available for all people with #diabetes who need them.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
June 13, 2025 at 1:50 PM
Insulin pens must be affordable and available for all people with #diabetes who need them.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
Why? For many people with diabetes, using pens to administer insulin is easier, more accurate, and preferred over more difficult-to-use vials and syringes.
Reposted by Michael Knappik
Hey @novonordisk.bsky.social, all #insulin pens must be available at $1 per pen, so that everyone can access the highest standard of diabetes treatment, especially as their cost of production is estimated to be as low as $0.94 per pen, including a profit.
June 12, 2025 at 3:39 PM
Hey @novonordisk.bsky.social, all #insulin pens must be available at $1 per pen, so that everyone can access the highest standard of diabetes treatment, especially as their cost of production is estimated to be as low as $0.94 per pen, including a profit.
Reposted by Michael Knappik
We welcome the news that @novonordisk.bsky.social will supply South Africa with analogue insulin pens, BUT...
The price Novo Nordisk is charging is TOO HIGH at $3.95 per pen.
msfaccess.org/msf-welcomes...
The price Novo Nordisk is charging is TOO HIGH at $3.95 per pen.
msfaccess.org/msf-welcomes...
MSF welcomes Novo Nordisk’s commitment to supply South Africa with analogue insulin pens, but the price must come down to $1 per pen
Novo Nordisk starts supply of analogue insulin pens to South Africa but price remains high still. All insulin pens must be available at $1 per pen.
msfaccess.org
June 12, 2025 at 3:39 PM
We welcome the news that @novonordisk.bsky.social will supply South Africa with analogue insulin pens, BUT...
The price Novo Nordisk is charging is TOO HIGH at $3.95 per pen.
msfaccess.org/msf-welcomes...
The price Novo Nordisk is charging is TOO HIGH at $3.95 per pen.
msfaccess.org/msf-welcomes...
Reposted by Michael Knappik
Time and again, Big Pharma has contested experts-backed generic price studies. Today’s drop in Bedaquiline’s price ($90), bringing it closer to its targeted generic price, is a proof that Pharmaceutical companies must stop profiteering off people's lives.
February 7, 2025 at 3:39 PM
Time and again, Big Pharma has contested experts-backed generic price studies. Today’s drop in Bedaquiline’s price ($90), bringing it closer to its targeted generic price, is a proof that Pharmaceutical companies must stop profiteering off people's lives.
Reposted by Michael Knappik
👇 #IDSky take note @thelancetinfdis.bsky.social has entered the conversation
The Lancet Infectious Diseases is on Bluesky now!
Have we missed anything? Quiet time of the year, isn't it...
👉 Follow us for the newest research and commentary in infectious diseases!
#IDSky
Have we missed anything? Quiet time of the year, isn't it...
👉 Follow us for the newest research and commentary in infectious diseases!
#IDSky
February 3, 2025 at 6:30 PM
👇 #IDSky take note @thelancetinfdis.bsky.social has entered the conversation
Reposted by Michael Knappik
